Biogen announced Wednesday that it is stopping its clinical trials of an Alzheimer’s drug, will no longer sell it, and is forsaking the ownership rights. Along with federal regulators, the company had faced major criticism over the development and pricing—at $56,000 per year—of Aduhelm. Biogen said it will press on with Leqembi, an Alzheimer’s drug it developed with Eisai, the Wall Street Journal reports. Leqembi has received full approval from the Food and Drug Administration and is on the market now. “When searching for new medicines, one breakthrough can be the foundation that triggers futu…